Firma Kuros Biosciences, Autor bei PR-Web

Kuros Biosciences reports results for the first six months of 2022

Posted on 9. August 20229. August 2022 by Firma Kuros Biosciences Posted in General Tagged bone, checkmate, chf, fibrin, flex, graft, kuros, magnetos, market, patients, posterolateral, pth, putty, statements, with

Financial highlights CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2022 Product sales increased by 58% to CHF 5.7 million Operational highlights FDA cleared MagnetOs Granules for use in expanded spinal indications FDA […]

Annual General Meeting of Kuros Biosciences approves all resolutions

Posted on 9. June 2022 by Firma Kuros Biosciences Posted in General Tagged biosciences, board, bonds, chf, company, financial, klg, kuros, media, report, risks, shareholders, statements, van, with

. Kuros Biosciences (SIX:KURN) today announced that its Annual General Meeting approved all resolutions proposed by the Board of Directors. The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and Consolidated Financial Statements for the year 2021 […]

Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial

Posted on 31. May 2022 by Firma Kuros Biosciences Posted in General Tagged bone, cell, cells, clinical, ECM, gold, graft, isass, kuros, magnetos, origin, patients, posterolateral, project, statements

Fusion rate 78%, vs 42% for autograft and 55-71% for other synthetic bone grafts First of five planned randomized controlled trials for MagnetOs Data will support product approvals at hospitals and within hospital systems Kuros Biosciences (“Kuros” or the “Company”), […]

Kuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S.

Posted on 18. May 2022 by Firma Kuros Biosciences Posted in General Tagged bone, cell, ECM, extender, graft, kuros, magnetos, market, packaging, patients, posterolateral, putty, statements, storage, with

Soft, moldable formulation that is ready to use with no need for thawing or mixing Becomes third commercial MagnetOs product Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the commercial launch of […]

Kuros Biosciences continues strong commercial roll-out of MagnetOs bone graft

Posted on 27. April 2022 by Firma Kuros Biosciences Posted in General Tagged bone, checkmate, ECM, fibrin, flex, graft, kuros, magnetos, market, patients, posterolateral, pth, royalty, statements, with

. Medical devices Q1 2022 sales accelerate, rising 102% over Q1 2021 FDA cleared MagnetOs Granules for expanded indications in spine and MagnetOs Flex Matrix as bone void filler in posterolateral spine Promising first-in-human data from Phase II trial of […]

Kuros Biosciences’s MagnetOs Flex Matrix Cleared by FDA for Spinal Indications

Posted on 21. April 2022 by Firma Kuros Biosciences Posted in General Tagged BMA, bone, bony, cells, easypack, extender, flex, graft, kuros, magnetos, patients, posterolateral, putty, statements, with

Clearance as a bone void filler for use in the posterolateral spine Third FDA clearance for MagnetOs in the last 7 months Product provides opportunity to de-risk U.S. commercialization plans Kuros Biosciences (“Kuros” or the “Company”), a leader in […]

Kuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-113) in treatment of open tibial shaft fractures

Posted on 20. January 2022 by Firma Kuros Biosciences Posted in Research / Development Tagged bone, cells, clinical, energy, fibrin, graft, kuros, market, patients, pth, research, spinal, statements, tibial, with

. Phase II data published in peer-reviewed Journal of Bone and Joint Surgery Healing rate at six months post-surgery was higher than standard of care Significantly de-risks development of Fibrin-PTH for spinal fusion Kuros Biosciences (“Kuros” or the “Company”), a […]

Kuros Biosciences reports continued increase in MagnetOs U.S. sales

Posted on 26. October 202126. October 2021 by Firma Kuros Biosciences Posted in General Tagged axis, bone, chf, extender, graft, implant, kuros, magnetos, patients, posterolateral, putty, revenues, statements, with, ytd

MagnetOs U.S. YTD sales increase 119% in 2021 compared to 2020 Kuros expanding MagnetOs range to increase perioperative solutions for surgeons Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today provided an update […]

Kuros Biosciences to showcase new MagnetOs products at NASS 2021 Annual Meeting

Posted on 28. September 2021 by Firma Kuros Biosciences Posted in General Tagged bone, bony, cells, cervical, easypack, extender, graft, kuros, magnetos, osseous, patients, posterolateral, putty, statements, with

. New products expand perioperative solutions for surgeons Data to be presented on new formulation of MagnetOs that includes a collagen carrier Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it […]

Kuros Biosciences Reports Results for First Half 2021

Posted on 11. August 202111. August 2021 by Firma Kuros Biosciences Posted in General Tagged bone, checkmate, chf, ECM, fibrin, gold, implant, kuros, magnetos, patients, posterolateral, pth, statements, with, wound

. Financial Highlights CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2021 Received CHF 5.5 million milestone payments from Checkmate Pharmaceuticals Acceleration of product sales to CHF 3.6 million, up from CHF 1.3 […]